A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States

Published:2021-03 Issue: Volume:223 Page:405-429
ISSN:0002-9394
Container-title:American Journal of Ophthalmology
language:en
Short-container-title:American Journal of Ophthalmology

Author:

Brown Gary C.^ORCID,Brown Melissa M.,Rapuano Sara B.,Boyer David

Publisher

Elsevier BV

Subject

Ophthalmology

Reference56 articles.

1. Patient preference-based cost-utility analysis of VEGF-inhibitor therapy for neovascular age-related macular degeneration in the United States in 2018;Brown;Am J Ophthalmol,2020

2. for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration;Rosenfeld;N Eng J Med,2006

3. for the Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR Study;Brown;Ophthalmology,2009

4. for the VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration;Heier;Ophthalmology,2012

5. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies;Schmidt-Erfurth;Ophthalmology,2014

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors Involved in Anti-VEGF Treatment Decisions for Neovascular Age-Related Macular Degeneration: Insights from Real-World Clinical Practice;Clinical Ophthalmology;2024-06

2. Prevalence and Risk Factors of Age-Related Macular Degeneration in South Korea: Korea National Health and Nutrition Examination Survey;Ophthalmic Epidemiology;2024-03-20

3. Häufigkeit und Wirkstoffverteilung intravitrealer Injektionen in deutschen Zentren 2015 bis 2021 – eine oregis-Studie;Die Ophthalmologie;2024-02-05

4. Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration;Ophthalmology Retina;2023-11

5. Recent evidence of economic evaluation of artificial intelligence in ophthalmology;Current Opinion in Ophthalmology;2023-07-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3